BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 11, Issue 12
This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (6602)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.
Item 
Count 
PDF538
WORD205
HTML3681
Figures (1-2)138
Tables (1-3)117
 Sum=4679
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse663
Download1260
 Sum=1923
Dec 27, 2019 (publication date) through Dec 5, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761]
URL: https://www.wjgnet.com/1948-5182/full/v11/i12/761.htm
Number Citing Articles
1
Julia Konrad, Ernst Eber, Vanessa Stadlbauer. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Paediatric Respiratory Reviews 2022; 42: 9 doi: 10.1016/j.prrv.2020.12.001
2
Lucile Regard, Clémence Martin, Jennifer Da Silva, Pierre-Régis Burgel. CFTR Modulators: Current Status and Evolving Knowledge. Seminars in Respiratory and Critical Care Medicine 2023; 44(02): 186 doi: 10.1055/s-0042-1758851
3
Aikaterini Kanavaki, Ino Kanavaki, Pavlos S. Zoumpoulis, Maria Moustaki, Konstantinos Douros, Ioanna Loukou. Changes in Shear Wave Elastography after Lumacaftor/Ivacaftor Treatment in Children with Cystic Fibrosis. Current Drug Safety 2023; 18(1): 93 doi: 10.2174/1574886317666220513105114
4
Kimberly McBennett, Christina J. MacAskill, Elise Keshock, Maryam Ghadimi Mahani, Jaime Mata, Alexander J. Towbin, Senthilkumar Sankararaman, Mitchell L. Drumm, Xin Yu, Clement L. Ren, Samya Z. Nasr, Katherine Kutney, Chris A. Flask. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. Journal of Cystic Fibrosis 2022; 21(2): e148 doi: 10.1016/j.jcf.2021.11.006
5
Adrienne P. Savant, Susanna A. McColley. Cystic fibrosis year in review 2019: Section 1 CFTR modulators. Pediatric Pulmonology 2020; 55(12): 3236 doi: 10.1002/ppul.25039
6
Mitchell L Ramsey, Michael R Wellner, Kyle Porter, Stephen E Kirkby, Susan S Li, Luis F Lara, Sean G Kelly, A James Hanje, Lindsay A Sobotka. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World Journal of Hepatology 2022; 14(2): 411-419 doi: 10.4254/wjh.v14.i2.411
7
Theresa Frantzen, Sara Barsky, Geralyn LaVecchia, Michelle Marowitz, Janice Wang. Evolving Nutritional Needs in Cystic Fibrosis. Life 2023; 13(7): 1431 doi: 10.3390/life13071431
8
Patience Eschenhagen, Carsten Schwarz. Viele Patienten mit Mukoviszidose haben jetzt eine bessere Lebensqualität. MMW - Fortschritte der Medizin 2021; 163(S1): 74 doi: 10.1007/s15006-021-9804-z
9
Pawel E. Ferdek, Daria Krzysztofik, Kinga B. Stopa, Agnieszka A. Kusiak, Milena Paw, Dawid Wnuk, Monika A. Jakubowska. When healing turns into killing – the pathophysiology of pancreatic and hepatic fibrosis. The Journal of Physiology 2022; 600(11): 2579 doi: 10.1113/JP281135
10
Almudena Marinero Martínez-Lázaro, Rosa María Girón Moreno, Fernando Casals Seoane, Óscar Cano-Valderrama, Luisa García-Buey. Cystic fibrosis with liver involvement in adults has a benign course. Results from a tertiary referral centre cohort. Revista Española de Enfermedades Digestivas 2022; 114 doi: 10.17235/reed.2022.9289/2022
11
Robert D. Baker, Susan S. Baker. Cystic Fibrosis-related Liver Disease: The Next Challenge. Journal of Pediatric Gastroenterology & Nutrition 2020; 71(4): 421 doi: 10.1097/MPG.0000000000002867
12
Leonardo Pozo, Fatimah Bello, Yamely Mendez, Salim Surani. Cystic fibrosis-related diabetes: The unmet need. World Journal of Diabetes 2020; 11(6): 213-217 doi: 10.4239/wjd.v11.i6.213
13
Daniel B. Karb, Linda C. Cummings. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Current Gastroenterology Reports 2021; 23(10) doi: 10.1007/s11894-021-00817-2
14
Katherine A. Despotes, Scott H. Donaldson. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022; 65: 102239 doi: 10.1016/j.coph.2022.102239
15
Katharina Staufer. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. International Journal of Molecular Sciences 2020; 21(22): 8586 doi: 10.3390/ijms21228586
16
Alexander J. Towbin, Wen Ye, Suiyuan Huang, Boaz W. Karmazyn, Jean P. Molleston, Prakash Masand, Daniel H. Leung, Samuel Chang, Michael R. Narkewicz, Adina L. Alazraki, A. Jay Freeman, Randolph K. Otto, Nicole Green, Ihab R. Kamel, Wikrom W. Karnsakul, John C. Magee, Jean Tkach, Joseph J. Palermo. Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasound. Pediatric Radiology 2023; 53(11): 2210 doi: 10.1007/s00247-023-05706-6
17
Jordan S. Sherwood, Jagdeesh Ullal, Katherine Kutney, Kara S. Hughan. Cystic fibrosis related liver disease and endocrine considerations. Journal of Clinical & Translational Endocrinology 2022; 27: 100283 doi: 10.1016/j.jcte.2021.100283
18
Jérémy Dana, Dominique Debray, Aurélie Beaufrère, Sophie Hillaire, Monique Fabre, Caroline Reinhold, Thomas F. Baumert, Laureline Berteloot, Valérie Vilgrain. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. Journal of Hepatology 2022; 76(2): 420 doi: 10.1016/j.jhep.2021.09.042
19
Michael R. Narkewicz. Cystic fibrosis liver disease in the post-modulator era. Current Opinion in Pulmonary Medicine 2023; 29(6): 621 doi: 10.1097/MCP.0000000000001017
20
Varinder S. Athwal, Jennifer A. Scott, Emer Fitzpatrick, Marion Rowland. Emerging clinical perspectives in cystic fibrosis liver disease. Current Opinion in Pulmonary Medicine 2021; 27(6): 593 doi: 10.1097/MCP.0000000000000824
21
I.M. Balfour-Lynn, J.A. King. CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis. Paediatric Respiratory Reviews 2022; 42: 3 doi: 10.1016/j.prrv.2020.05.002
22
Keyan Zarei, Mallory R. Stroik, Nick D. Gansemer, Andrew L. Thurman, Lynda S. Ostedgaard, Sarah E. Ernst, Ian M. Thornell, Linda S. Powers, Alejandro A. Pezzulo, David K. Meyerholz, David A. Stoltz. Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model. Laboratory Investigation 2020; 100(11): 1388 doi: 10.1038/s41374-020-0474-8
23
A. G. Chermensky, T. E. Gembitskaya, A. V. Orlov, V. R. Makhmutova. The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosis. Meditsinskiy sovet = Medical Council 2022; (4): 98 doi: 10.21518/2079-701X-2022-16-4-98-106
24
Murali K. Yanda, Adi Zeidan, Liudmila Cebotaru. Ameliorating liver disease in an autosomal recessive polycystic kidney disease mouse model. American Journal of Physiology-Gastrointestinal and Liver Physiology 2023; 324(5): G404 doi: 10.1152/ajpgi.00255.2022
25
Joseph J Valamparampil, Girish L Gupte. Cystic fibrosis associated liver disease in children. World Journal of Hepatology 2021; 13(11): 1727-1742 doi: 10.4254/wjh.v13.i11.1727
26
David Drummond, Jérémy Dana, Laureline Berteloot, Elena K. Schneider-Futschik, Frédérique Chedevergne, Céline Bailly-Botuha, Thao Nguyen-Khoa, Mathieu Cornet, Muriel Le Bourgeois, Dominique Debray, Muriel Girard, Isabelle Sermet-Gaudelus. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. Journal of Cystic Fibrosis 2022; 21(2): 212 doi: 10.1016/j.jcf.2021.07.018
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345